Disease: Central neuroblastoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 Biomarker disease BEFREE Besides, the expression of MDR, LRP-1 and MRP-1 was also increased in NDRG1 overexpressing cells, implying NDRG1-mediated pathways in multidrug resistance of neuroblastoma. 26653549 2015
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 Biomarker disease BEFREE Endogenous substrates of ABCC1 and ABCC4 that may be potential candidates affecting neuroblastoma biology include molecules such as prostaglandins and leukotrienes. 25640269 2015
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 GeneticVariation disease BEFREE Our aim was to determine the prognostic implications of ABCC1 polymorphisms in neuroblastoma. 21317832 2011
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 Biomarker disease BEFREE Inhibition of ABCC1 statistically significantly inhibited neuroblastoma development in hMYCN transgenic mice (mean age for palpable tumor: treated mice, 47.2 days; control mice, 41.9 days; hazard ratio [HR] = 9.3, 95% confidence interval [CI] = 2.65 to 32; P < .001). 21799180 2011
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE To this end, we used an inducible siRNA (small interfering RNA) expression system to silence the expression of MRP1 and MDR1 in human neuroblastoma SH-SY5Y cells. 18713069 2009
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 Biomarker disease BEFREE Therefore, Reversan represents a new class of nontoxic MRP1 inhibitor, which may be clinically useful for the treatment of neuroblastoma and other MRP1-overexpressing drug-refractory tumors by increasing their sensitivity to conventional chemotherapy. 19654298 2009
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE Given the importance of MRP1 overexpression in neuroblastoma, MRP1 inhibition may be a clinically relevant approach to improving patient outcome in this disease. 18085475 2007
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. 16575006 2006
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE Given the importance of MRP1 overexpression in neuroblastoma, MRP1 inhibition may be a clinically relevant approach to improving patient outcome in this disease. 15979785 2005
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE These findings indicate that by interacting with E-box elements within the promoter, MYCN can upregulate MRP1 expression and modulate drug resistance in NB. 14737110 2004
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE To rule out the possibility that multidrug resistance (MDR) genes are involved in development of acquired drug resistance in murine neuroblastoma (rMNB/MDL) cells made resistant to MDL, the expression of Mdr1a, Mdr1b, Mdr2 (multidrug resistance/P-glycoprotein), and Mrp-1 (multidrug resistance associated protein) was examined in rMNB-MDL cells. 11172599 2001
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. 11720446 2001
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE Our results give evidence that MDR in neuroblastomas might be caused by multiple resistance factors and that a higher proliferation rate of neuroblastoma cells possibly based on altered MYCN gene expression is associated with enhanced MRP, CYCA and TOPO IIalpha gene expression. 10425316 1999
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected with MYCN antisense RNA constructs. 10348353 1999
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE The forced expression of N-myc failed to enhance the expression of MRP in N-myc transfected neuroblastoma cell lines. cMOAT was rarely expressed in the neuroblastomas, but was frequently expressed in the malignant liver tumors. 10081488 1998
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE To address this hypothesis, we have examined the relationship between MYCN and MRP gene expression in neuroblastoma tumours and cell lines. 9516823 1997
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE High levels of MRP gene expression in patients with neuroblastoma correlate strongly with poor outcome. 8532000 1996
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.100 AlteredExpression disease BEFREE Expression of the MRP gene is thus common in both primary neuroblastoma tumors and cultured cell lines, and correlates with amplification and overexpression of the N-myc oncogene, which is central to the malignant phenotype of this disease. 7923112 1994